Table 3 Comparison of commonly observed toxicities between 2.5 g/m2 HDMTX cycles and 5 g/m2 HDMTX cycles (N = 120)
2.5 g/m2 HDMTX cycles (N = 60) | 5 g/m2 HDMTX cycles (N = 60) | p | |
|---|---|---|---|
N (%) | |||
Hematological toxicities | |||
Neutropenia | |||
No | 16 (26.7) | 12 (20.0) | “χ2 test” p=0.388 |
Yes | 44 (73.3) | 48 (80.0) | |
G3–4 | 35 (58.3) | 35 (58.3) | “χ2 test” p=1.000 |
Anemia | |||
No | 13 (21.7) | 15 (25.0) | “χ2 test” p=0.666 |
Yes | 47 (78.3) | 45 (75.0) | |
G3–4 | 17 (28.3) | 18 (30.0) | “χ2 test” p=0.841 |
Thrombocytopenia | |||
No | 39 (65.0) | 44 (73.3) | “χ2 test” p=0.323 |
Yes | 21 (35.0) | 16 (26.7) | |
G3–4 | 10 (16.7) | 9 (15.0) | “χ2 test” p=0.803 |
Febrile neutropeniaa | |||
No | 45 (75.0) | 44 (73.3) | “χ2 test” p=0.835 |
Yes | 15 (25.0) | 16 (26.7) | |
Hepatic toxicity | |||
Increased ALT | |||
No | 46 (76.7) | 40 (66.7) | “χ2 test” p=0.224 |
Yes | 14 (23.3) | 20 (33.3) | |
G3–4 | 2 (3.3%) | 4 (6.7%) | FEp=0.679 |
Increased AST | |||
No | 44 (73.3) | 43 (71.7) | “χ2 test” p=0.838 |
Yes | 16 (26.7) | 17 (28.3) | |
G3–4 | 2 (3.3%) | 2 (3.3%) | FEp=1.000 |
Gastrointestinal toxicity | |||
Oral mucositis | |||
No | 32 (53.3) | 44 (73.3) | “χ2 test” p=0.023 |
Yes | 28 (46.7) | 16 (26.7) | |
G3–4 | 10 (16.7%) | 10 (16.7%) | “χ2 test” p=1.000 |
Nephrotoxicity | |||
Increased creatinine | |||
No | 41 (68.3) | 39 (65.0) | “χ2 test” p=0.699 |
Yes | 19 (31.7) | 21 (35.0) | |
G3–4 | 1 (1.7%) | 1 (1.7%) | FEp=1.000 |
Hospitalizationb | |||
No | 40 (66.7) | 48 (80.0) | “χ2 test” p=0.099 |
Yes | 20 (33.3) | 12 (20.0) | |
Length of hospitalization | (N = 20) | (N=12) | |
Median (IQR) | 4 (2–7.5) | 7 (6–10.5) | “U test” p=0.012 |
Min.–Max. | 2–14 | 4–12 | |